On September 25, Wuhan YZY Biopharma Co., Ltd. ("YZY Biopharma", HK:02496) was listed on the Hong Kong Stock Exchange. In this listing, YZY Biopharma raised a total of about HK $176 million.

YZY Biopharma are a biotechnology company dedicated to the development of bispecpecic antibody (BsAb) -based therapies for the treatment of cancer-related complications, cancer and age-related eye diseases. The company have designed and developed a pipeline of seven clinical stage drug candidates.

China Securities acted as the sole sponsor of the listing.

Cooley HK, Jingtian & Gongcheng and King & Wood Mallesons providing professional services to issuers on Hong Kong law, Chinese law and Chinese intellectual property law respectively; Sidley Austin and Merits & Tree Law Offices are the Hong Kong and China legal advisors of the underwriters respectively.

Deloitte acted as auditor.

Frost & Sullivan is an industry consultant.